Emerging therapeutic strategies for cystinosis

For over 40 years, oral cysteamine has been the mainstay of therapy for cystinosis. While it has been of great benefit, slowing organ deterioration and prolonging life, cysteamine is not well tolerated and may not rescue all pathogenic mechanisms driving the disease. Of late, research groups around...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul Goodyer, Elena Torban
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Pediatrics
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2025.1601409/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849328786599837696
author Paul Goodyer
Paul Goodyer
Elena Torban
Elena Torban
author_facet Paul Goodyer
Paul Goodyer
Elena Torban
Elena Torban
author_sort Paul Goodyer
collection DOAJ
description For over 40 years, oral cysteamine has been the mainstay of therapy for cystinosis. While it has been of great benefit, slowing organ deterioration and prolonging life, cysteamine is not well tolerated and may not rescue all pathogenic mechanisms driving the disease. Of late, research groups around the world have been pursuing various novel therapeutic strategies. Here we select just four of many examples - two that address events downstream of the missing Cystinosin protein and two that aim to address the upstream CTNS mutation. Our aim is to update the cystinosis community on some of the exciting work in progress. We have drawn from preliminary reports and oral presentations at cystinosis meetings. While each approach requires further work and critical analysis, the sheer number and variety of these potential therapies is cause for hope.
format Article
id doaj-art-349b410238da4fc2a71068bf96330e2b
institution Kabale University
issn 2296-2360
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pediatrics
spelling doaj-art-349b410238da4fc2a71068bf96330e2b2025-08-20T03:47:28ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602025-05-011310.3389/fped.2025.16014091601409Emerging therapeutic strategies for cystinosisPaul Goodyer0Paul Goodyer1Elena Torban2Elena Torban3Department of Pediatrics, McGill University, Montréal, QC, CanadaResearchInstitute of the McGill University Health Centre, Montréal, QC, CanadaResearchInstitute of the McGill University Health Centre, Montréal, QC, CanadaDepartment of Medicine, McGill University, Montréal, QC, CanadaFor over 40 years, oral cysteamine has been the mainstay of therapy for cystinosis. While it has been of great benefit, slowing organ deterioration and prolonging life, cysteamine is not well tolerated and may not rescue all pathogenic mechanisms driving the disease. Of late, research groups around the world have been pursuing various novel therapeutic strategies. Here we select just four of many examples - two that address events downstream of the missing Cystinosin protein and two that aim to address the upstream CTNS mutation. Our aim is to update the cystinosis community on some of the exciting work in progress. We have drawn from preliminary reports and oral presentations at cystinosis meetings. While each approach requires further work and critical analysis, the sheer number and variety of these potential therapies is cause for hope.https://www.frontiersin.org/articles/10.3389/fped.2025.1601409/fullcystinosistherapeutic strategiesmRNApro-druggene therapyflavinoids
spellingShingle Paul Goodyer
Paul Goodyer
Elena Torban
Elena Torban
Emerging therapeutic strategies for cystinosis
Frontiers in Pediatrics
cystinosis
therapeutic strategies
mRNA
pro-drug
gene therapy
flavinoids
title Emerging therapeutic strategies for cystinosis
title_full Emerging therapeutic strategies for cystinosis
title_fullStr Emerging therapeutic strategies for cystinosis
title_full_unstemmed Emerging therapeutic strategies for cystinosis
title_short Emerging therapeutic strategies for cystinosis
title_sort emerging therapeutic strategies for cystinosis
topic cystinosis
therapeutic strategies
mRNA
pro-drug
gene therapy
flavinoids
url https://www.frontiersin.org/articles/10.3389/fped.2025.1601409/full
work_keys_str_mv AT paulgoodyer emergingtherapeuticstrategiesforcystinosis
AT paulgoodyer emergingtherapeuticstrategiesforcystinosis
AT elenatorban emergingtherapeuticstrategiesforcystinosis
AT elenatorban emergingtherapeuticstrategiesforcystinosis